

JC10 Rec'd PCT/PTO 25 MAR 2005

#4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re the Application of: Rudolf WANK et al.

Serial No.: 10/519,803-

Filed: December 29, 2004

For: USE OF DOPAMINE RECEPTOR AGONISTS FOR THE TREATMENT
OF CUTANEOUS TUMORS, WARTS AND SCARS

Attorney Docket Number: 043163

Customer Number: 38834

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §1.97(b)

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Date: March 25, 2005

Sir:

In compliance with 37 C.F.R. §1.56, Applicants direct the attention of the Patent and Trademark Office to the documents listed on the attached PTO/SB/08. This paper is being filed within the time periods set forth in 37 C.F.R. §1.97(b). A copy of each non-U.S. document is enclosed herewith.

If there are any fees due in connection with the filing of this paper, please charge Deposit Account No. 50-2866.

Respectfully submitted,

WESTERMAN, HATTORI, DANIELS & ADRIAN, LLP

Sadao Kinashi


Registration No.: 48,075

Telephone: (202) 822-1100

Facsimile: (202) 822-1111

SK/II

Enclosure: PTO/SB/08 and 13 Documents



Complete if Known

(Use as many sheets as necessary)

of

Application Number	10/519,803
Filing Date	December 29, 2004
First Named Inventor	Rudolf WANK
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	043163

[illegible]


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁹
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	2	GB 2 273 873 A	07-06-1994	Univ. of Sheff.		✓
	3	WO 99/50393	10-07-1999	PCT		✓
	4	WO 00/01720	01-13-2000	Harvard College		✓

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Use form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/519,803
	Filing Date	December 29, 2004
	First Named Inventor	Rudolf WANK
	Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	043163

Sheet

of

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	LIST et al., Arzneiformenlehre, Wiss. Verlagsges. Stuttgart, 1985	
	2	SUCKER et al., Parmazeutische Technologie, Thieme Verlag, Stuttgart, 1978	
	3	PAWLIKOWSKI M. et al., Cell Tissue Res. 1979, 202 (1): 165-169	
	4	PAWLIKOWSKI M. et al., Neural Transm 1983; 56 (1): 91-95	
	5	ORLOWSKI et al., Biochemical Biophys. Res. Commun. (1998) 244, pp. 481-488	
	6	HINCHLIFFE et al., Evidence for dissociation of histone mRNA expression., J. Phathol (1996) 178 (3) 249-254	
	7	Sanchez REGANA et al., Abstract of Psoriasis in association with prolactinoma: three cases. (2000) 143 (4)864-7	
	8	GIASUDDIN et al., Abstract of Prolactin: does it have a role in the pathogenesis of psoriasis. Dermatology (1998) 197 (2) 119-22	
	9	SLOMINSKI et al., Abstract of Abstract of Human skin expresses growth hormone but not the prolactin gene. Lab. Clin. Med. (2000) 136 (6) 476-81	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.